Brain-derived neurotrophic factor gene val66met polymorphism is a risk factor for attention-deficit hyperactivity disorder in a Turkish sample by Özturk, Önder et al.
INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a com-
mon and heritable neurodevelopmental disorder that affects 
8% to 12% of school-aged children.1 ADHD is characterized 
by inattention, hyperactivity, and impulsivity and leads to 
Print ISSN 1738-3684 / On-line ISSN 1976-3026
OPEN ACCESS
518  Copyright © 2016 Korean Neuropsychiatric Association  
many problems related to social, academic and behavioral 
areas of life. The etiology of ADHD is not completely under-
stood, but the estimated heritability is approximately 75%, 
and thus it is generally thought to have a having a genetic ba-
sis.2 Dysregulations of the catecholaminergic neurotransmit-
ter systems are thought to play important roles in ADHD, 
and the dopamine and norepinephrine systems have been 
studied extensively.3
Brain-derived neurotrophic factor (BDNF) is a member of 
the neurotrophin superfamily and plays critical roles in the se-
rotonergic,4 glutamatergic,5 noradrenergic,6 and dopaminer-
gic7 neurotransmitter systems, which are important for the 
pathogenesis of the ADHD. Chen et al.8 reported that the 
plasma concentrations of BDNF are significantly lower in pa-
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tients than in healthy controls, although these authors found 
that the BDNF gene polymorphism does not affect plasma 
BDNF levels.
Polymorphisms of the human BDNF gene, which is locat-
ed on chromosome 11p13, have been studied in several psy-
chiatric disorders. The most frequent is the Val66Met (rs6265) 
guanine (G)-to-adenine (A) single-nucleotide polymorphism 
(SNP) at nucleotide 196 that results in an amino acid substitu-
tion of methionine (Met) for valine (Val).9 This polymorphism 
impairs the packaging of proBDNF and results in reduced 
depolarization-induced secretion of BDNF from neurosecre-
tory cells and cortical neurons. However, in the same study, 
the authors showed that the constitutive secretion of mature 
BDNF is not affected by this polymorphism and that the 
basal release of BDNF continues.10 The Val (G) allele of the 
Val66Met polymorphism has been reported to be associated 
with bipolar disorder and schizophrenia in previous stud-
ies.11,12 Additionally the Met allele of the Val66Met polymor-
phism has been reported to be associated with the restrictive 
type of anorexia nervosa.13 Sen et al.14 reported that the Met 
allele has a protective effect in depression.
Previous studies have reported inconsistent results regard-
ing the relationship between the BDNF gene and ADHD. 
Some of the studies have reported a positive association be-
tween the Val66Met polymorphism of BDNF and ADHD. 
One of these studies was conducted by Lanktree et al.15 who 
reported a positive association of the Val allele with ADHD 
in adult patients. In another study that consisted of a family 
based-sample of 341 ADHD probands also found a relation-
ship between the Val allele and ADHD.16 In contrast to these 
results, some studies have reported no association between 
the BDNF Val66Met polymorphism and ADHD.17-19
Studies of the cognitions related to ADHD have shown that 
ADHD children often perform poorly on tasks of working 
memory and exhibit impairments in spatial and verbal com-
ponents.20,21 Lee et al.22 reported no association between BDNF 
alleles and working memory abilities in their sample of ADHD 
families. Mice with an inactivated BDNF gene have exhibit 
significantly more locomotor activity when stressed than nor-
mal mice.23 Additionally, animal studies have revealed that 
BDNF is critical for learning and working memory.24,25
In the present study, we hypothesized that this BDNF gene 
polymorphism might be involved in the pathogenesis of 
ADHD and influence clinical presentations including neuro-
cognition and symptoms. Therefore, we aimed to evaluate 
the associations between the Val66Met polymorphism of the 
BDNF gene and ADHD and to assess the effects of this BDNF 
polymorphism on the neurocognitive profile and clinical 
symptomatology of ADHD. 
METHODS
Study design
The present study included 201 ADHD subjects [101 AD-
HD-combined (ADHD-C) and 100 ADHD-predominantly 
inattentive type (ADHD-I)] and 99 typically developing (TD) 
subjects aged 8 to 15 years who were consecutively assessed in 
the child and adolescent psychiatry clinic of Ege University 
from December 2011 to March 2013. The parents provided 
written informed consent. The Ethics Committee of Pamuk-
kale University approved the study protocol.
Participants
The inclusion criteria for both the ADHD and TD subjects 
were the following: 1) an estimated intelligence quotient (IQ) 
greater than 80, 2) no history of head injury with loss of con-
sciousness, 3) no neurological or other serious medical disease, 
4) no prior use of stimulants, and 5) no use of psychotropic 
medication within the last six months. For the ADHD sub-
jects, the additional criterion of a lack of history of any psychi-
atric disorder other than oppositional defiant disorder (ODD) 
was also included. For the TD controls, the additional criterion 
of a lack of any psychiatric disorder was included. 
Diagnostic procedures
Initially, the families and teachers completed the Child Be-
havior Checklist (CBCL),26 the Teacher’s Report Form (TRF),26 
and the DSM-IV Disruptive Behavior Disorders Rating Scale-
teacher and parent forms.27 The subjects with inattentive 
scores that were 1 SD greater than the age norms for these 
scales were invited to participate in the diagnostic portion of 
the study. This procedure was performed to guarantee that 
the inattentive symptoms were adequately represented in all 
of the ADHD types assessed. Thereafter, a semi-structured 
interview (i.e., the Kiddie-Schedule for Affective Disorders 
and Schizophrenia, present and life time version-K-SADS-
PL) was applied to parents by a senior child psychiatry resi-
dent.28 Additionally, we assessed the participants estimated 
IQs using the vocabulary and block design subtests of the 
WISC-R.
Two experienced child psychiatrists who were blinded to 
the first diagnostic assessment conducted confirmatory sec-
ond diagnostic interviews with the participants with positive 
ADHD diagnoses in the first KSDAS-PL interview. The par-
ents and subjects were also interviewed according to the K-
SADS-PL. “A best estimate procedure” was used to determine 
the final diagnoses.29 Three subjects refused to attend the 
second diagnostic interview, and disagreements the between 
interviewers regarding the ADHD types/comorbid diagnoses 
occurred in 10 cases. Thirteen subjects were excluded from 
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the second diagnostic part of the study. Unrelated healthy con-
trols were also recruited from the same community and were 
matched as well possible to the ADHD patients in terms of 
age and gender. The exact same diagnostic procedure was 
applied for the assessments of the controls. However, we re-
quired that the TD subjects exhibited inattentive scores that 
were one standard deviation below the means for the child’s 
age on the CBCL, TRF, and ADHD-RS-IV scales. Conse-
quently, 101 ADHD-C, 100 ADHD-I type and 99 TD sub-
jects were included in the study.
Neuropsychological evaluation
All cases in the study were assessed using a standardized 
neuropsychological battery (CNS-VS) that included tests ad-
dressing the neuropsychological constructs known to be asso-
ciated with ADHD. The battery included tests that measured 
verbal and visual memory, finger tapping, digit symbol coding, 
the Stroop test, a test of shifting attention and the continuous 
performance test (CPT). Six main scores, including the neuro-
cognitive index, total memory, reaction time, complex atten-
tion, cognitive flexibility, and psychomotor speed, were ob-
tained.30
DNA extraction and genotype determination
DNA was extracted from saliva samples for genotyping. 
Genotypes were determined using a TaqManTM fluorogenic 
5’-nuclease assay with TaqMan Probes. All reactions were car-
ried out following the manufacturer’s protocol. Primer Ex-
press 3.0 (Applied Biosystems) was used to design both the 
PCR primers and the TaqMan probes. For BDNF Gene Val-
66Met (rs6265) polymorphisms, custom made primers and 
probes are as follows: Forward Primer 5’-AGGCAGGTTCA 
AGAGGCTTGA-3’, Reverse Primer 5’-TTCTGGTCCTCAT 
CCAACAGCT-3’, Probe G: 5’-Yakima Yellow-TGA(pdC)
A(pdC)TTT(pdC)GAA(pdC)ACGTGATA-BHQ-1-3’, Probe 
A: 5’-FAM-TGA(pdC)A(pdC)TTT(pdC)GAA(pdC)A(pdC)
ATGATA-BHQ-1-3’. Single nucleotide polymorphism am-
plification assays were performed according to the manufac-
turer’s instructions.In brief, 25 μL of reaction solution con-
taining 30 ng of DNA was mixed with 12.5 μL of 2X TaqMan 
Universal PCR Master Mix (Applied Biosystems) and 900 
nmol of each primer, 200 nmol of each probe. Reaction con-
ditions consisted of preincubation at 60°C for 1 minute and 
at 95°C for 10 minute, followed by 40 cycles at 95°C for 15 
second and at 60°C for 1 minute. Amplifications and analysis 
were performed in an ABI Prism 7500 Real-Time PCR Sys-
tem (Applied Biosystems), using the SDS 2.0.6 software for 
allelic discrimination (Applied Biosystems).
Statistical analyses
The data analyses were performed using the statistical pack-
age for the SPSS 17.0 version for PC, and p-values <0.05 were 
considered statistically significant. Chi-square tests were ap-
plied to the categorical variables, and t-tests were applied to the 
continuous variables for the genotype group comparisons. We 
performed the multivariate analysis of variance (MANOVA) 
by assigning the age and gender as covariates to control the ef-
fects of these parameters on ADHD-related symptoms. Post-
hoc comparisons were carried out using Bonferroni correction 
and lower than 0.025 p values were accepted as statistically sig-
nificant for MANOVA because of the presence of two com-
parison genotype groups.
RESULTS
Two hundred and one patients with ADHD and 99 TD 
subject were involved the present study. The mean age of the 
ADHD group was 10.78±2.01 years, and the mean age of the 
TD group was 10.73±1.92 years. There was no difference in 
mean age (t=-0.190, p=0.85) between the groups. Although 
male predominance was provided in both groups of ADHD 
and TD, there was a significant difference between the pa-
tients and TD groups in terms of gender distribution. So-
ciodemographic and clinical characteristic of the participants 
were shown in Table 1.
Genetic assessments
The genotype determinations revealed that only 10 subjects 
(3.3%) among both the ADHD and TD groups had the AA 
genotype. Therefore, the sample was grouped into GG geno-
types and A-containing (GA+AA) genotypes (Table 2). The 
data analyses revealed significant differences in the genotypic 
frequency distributions of the Val66Met polymorphism be-
tween the ADHD and TD groups. The GG genotype was sig-
nificantly more frequent among the patients with ADHD than 
the TD participants (χ2=6.16, p=0.017). Additionally, the geno-
type frequency distributions of Val66Met polymorphism be-
tween the TD groups, ADHD-C subtype and ADHD-I subtype 
groups were found to be significantly different (χ2=6.16, 
p=0.046). The GG genotype was significantly more frequent in 
the ADHD-C group than the TD group. However, the frequen-
cy distributions of the GG genotype and A-containing geno-
types between the subtypes of ADHD did not differ (Table 2).
Assessments of ADHD-related symptoms 
In our study, the teacher-rated hyperactivity and inatten-
tion symptom counts and total scores were higher among the 
GG genotype group than the A-containing genotype group 
(p=0.031, p=0.025). Regarding the CBCL scores, there were 
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no significant differences between the Val66Met polymor-
phism subgroups. However, the appropriate behavior score 
of the TRF was significantly lower in the GG genotype group 
than the A-containing genotypes group (p=0.031) (Table 3). 
When we performed the multivariate analysis of variance 
(MANOVA) by assigning the age and gender as covariates to 
control the effects of these parameters on the ADHD-related 
symptoms, and we found that the appropriate behavior score 
of the TRF remained to be statistically significantly different 
between the polymorphism groups in patients with ADHD 
(λ=.957, F=2.92, p=0.009) (Table 3).
Neuropsychological findings
The neuropsychological performances, including verbal and 
visual memory, finger tapping, digit symbol coding, the Stroop 
test, the test of shifting attention, and the vocabulary and block 
design subtests of the WISC-R and the CPT of the Val66Met 
polymorphism groups was not found to be significantly differ-
ent (p>0.05). Additionally, the neuropsychological battery 
scores did not differ within the entire group (ADHD and TD) 
or within the TD group according to the BDNF polymor-
phism (p>0.05) (Table 3).
DISCUSSION
In the present study, we found a positive association be-
tween the BDNF gene Val66Met SNP polymorphism and 
ADHD that the GG genotype was more frequent in the pa-
tients with ADHD and the ADHD-C subtype than in the TD 
group. BDNF is a member of the neurotrophins family that 
has a crucial role in neuronal developmental process, neuro-
plasticity and neuronal function.31 Thus investigation of ef-
fects of BDNF gene polymorphism on ADHD which is a neu-
rodevelopmental disorder is great importance. The Val66Met 
polymorphism of BDNF can affect the intracellular traffick-
ing and can reduce depolarization-induced secretion of the 
BDNF. However, Chen et al.10 reported that the mature BDNF 
is not affected by the polymorphism and its basal release 
continues. The neuropsychiatric studies suggested that the 
levels of circulating BDNF which is reflect the level of brain-
tissue BDNF32 was effected by the polymorphism. Reduced 
BDNF levels were reported in Met carriers patients with de-
Table 2. Distributions of Val66Met polymorphism
GG Genotype (N, %) GA, AA Genotype (N, %) χ2 p
Distributions of Val66Met polymorphism 
  between ADHD and TD
TD 60 (60.6) 39 (39.4) 5.74 0.017*
ADHD 149 (74.1) 52 (25.9)
Distributions of Val66Met polymorphism 
  between ADHD subtypes and TD
TD 60 (60.6) 39 (39.4) 6.16 0.046*
ADHD-C 77 (76.2) 24 (23.8)
ADHD-I 72 (72.0) 28 (28.0)
Chi-square test. *statistically significance p<0.05. ADHD: attention-deficit hyperactivity disorder, ADHD-C: ADHD-combined type, ADHD-
I: ADHD predominantly inattentive type, TD: typically developing subjects
Table 1. Socio-demographic characteristics and ADHD rating scale scores
ADHD (N=201) TD (N=99) p
Test statistic or 
group comparison
Age, years (mean±SD) 10.78±2.01 10.73±1.92 0.850   t=-0.190
Gender (F/M) 44/157 45/55 <0.001 χ2=17.12
Estimated IQ (mean±SD) 105.06±18.52 111.50±20.95 0.007  t= 2.71
Parental inattention symptom counts (mean±SD) 6.60±2.19 0.32±0.87 <0.001 ADHD>TD
Parental hyperactivity/Impulsivity symptom counts 
  (mean±SD)
4.35±3.34 0.22±0.59 <0.001 ADHD>TD
Teacher inattention symptom count (mean±SD) 6.55±2.25 0.24±0.69 <0.001 ADHD>TD
Teacher hyperactivity symptom count (mean±SD) 4.16±3.21 0.20±0.60 <0.001 ADHD>TD
Data are presented as the means±standard deviations (SD) or n, as appropriate. ADHD: attention-deficit hyperactivity disorder, TD: typically 
developing children, IQ: intelligence quotient
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pression33 and schizophrenia.34 Conversely, studies demon-
strated that the healthy human with Met allele carriers have 
increased circulating BDNF levels.35,36 Li et al.37 indicated that 
the females who were Met/Met genotype carriers with ADHD 
had a tendency of increased plasma BDNF levels than Val al-
lele carriers however the difference was not statistically sig-
nificant. Taken together these data and our result, it may be 
suggested that the Val allele may contribute to pathogenesis 
of ADHD.
The relationship between ADHD and the BDNF gene has 
been investigated in many studies. In accordance with our 
findings, Kent et al.16 reported a positive association with the 
Val (G) allele, particularly when this allele is paternally trans-
mitted, in children with ADHD. Similarly, Aureli et al.37 re-
ported that the G allele of the Val66Met polymorphism is sig-
nificantly associated with ADHD. In another study conducted 
by Li et al.,38 a higher frequency of the Val allele was found in 
females with ADHD than in controls. Another study conduct-
ed by Lanktree et al.,15 which has currently only been report-
ed in abstract form, described evidence for the involvement 
of the Val allele of the Val66Met polymorphism in both case 
control and trio analyses of adult ADHD patients. In light of 
these results, it may be suggested that there is a positive asso-
ciation between the BDNF polymorphism and ADHD and 
moreover that this association is more prominent in terms of 
hyperactivity than inattention. Furthermore, we speculated 
that the Val allele of the Val66Met polymorphism is a risk 
factor for ADHD. Conversely, in some previous studies, no 
evidence of an association between the Val66Met polymor-
phism and ADHD has been found.17-19,39,40 These contradic-
tory findings may be due to genetic and clinical heterogene-
ity, the use of different diagnostic practices, differences of in 
the ADHD subtype distributions across the studies, differ-
ences in comorbidities, and the insufficient sample sizes of 
Table 3. Comparison of genotype groups in terms of symptoms and neuropsychological findings in patients
GG genotype
mean/SD
GA, AA genotype
mean/SD
p* p† Group comparison
Attention deficit, hyperactivity symptoms score
Teacher hyperactivity and inattention 
  symptom count
11.1±4.3 9.5±4.7 0.03* 0.08 GG>GA, AA
Teacher hyperactivity and inattention 
  total score
25.8±11.2 21.7±11.4 0.02* 0.07 GG>GA, AA
Parent hyperactivity and inattention 
  symptom count
10.8±4.2 11.0±4.3 0.74
Parent hyperactivity and inattention 
  total score
25.1±10.7 26.3±11.8 0.52
Child Behavior Checklist (CBCL)
Internalizing total score 58.3±11.0 60.0±10.9 0.33
Externalizing total score 56.1±11.4 56.3±11.0 0.95
Total behavior  problems s. 59.8±10.0 60.5±11.0 0.70
Teacher’s Report Form (TRF)
Behaving appropriately 46.1±7.9 49.9±11.6 0.03* 0.009† GG<GA, AA
Internalizing total score 57.9±8.7 57.5±9.0 0.76
Externalizing total score 54.7±9.3 54.7±9.6 0.98
Total behavior  problems s. 56.9±9.2 55.9±8.3 0.48
Neuropsychological  battery (CNS-VS)
Total memory score 85.3±21.2 84.5±22.6 0.83
Reaction time score 73.7±25.0 74.1±28.9 0.91
Complex attention score 77.1±20.2 78.0±18.5 0.76
Cognitive flexibility score 90.9±17.7 93.7±17.6 0.22
Psychomotor speed score 84.9±18.0 85.4±17.7 0.86
Neurocognitive index score 81.1±12.0 81.6±12.8 0.78
*independent simples t-test, statistically significance p<0.05, †multivariate analysis of variance (MANOVA) by assigning the age and gender 
as covariates (Post-hoc comparisons were carried out using Bonferroni correction and less than 0.025 p values were accepted as statistically 
significant)
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the studies.40 It is possible that the above mentioned reasons 
have masked a real association between this disorder and the 
BDNF gene polymorphism. Additionally, epigenetic factors 
or mechanisms, such as environmental factors, abnormal 
imprinting of the genes, and neuroanatomically tissue-spe-
cific expression patterns, might affect the pathogenesis of 
ADHD.16 A better understanding of the relationships of varia-
tions in genes, such as BDNF, with the pathogenesis of ADHD 
may require analyses of gene-gene and gene-environment 
interactions.
The distributions of the Val66Met polymorphism did not 
differ between the ADHD-C and ADHD-I subtypes in our 
study. Similarly, in a meta-analysis, Sánchez-Mora et al.40 re-
ported that there is no statistically significant effect of the 
Val66Met polymorphism of the BDNF gene on ADHD sub-
types. This finding may indicate that the contribution of 
BDNF to ADHD is not subtype-specific40 or, alternatively, 
that the small sample sizes of the studies, including our own, 
have been insufficient to uncover an association.
In our study, the teacher-rated hyperactivity and inatten-
tion symptom counts and total scores were higher, and the 
appropriate behavior scores of the TRF were significantly 
lower in the GG genotype group than in the A-containing 
genotype groups. However the multivariate analysis of vari-
ance by assigning the age and gender as covariates have shown 
that appropriate behavior score of the TRF remained to be 
statistically significantly lower in GG genotype group of pa-
tients with ADHD. As mentioned previously, the GG geno-
type was observed more frequently in the patients than the 
controls in the present study, which is consistent with the re-
sults of some of the previous studies. Therefore, it may be 
suggested that the GG genotype may have a role in the patho-
genesis of ADHD and may also affect the clinical symptom-
atology of ADHD. There are few studies that have assessed 
BDNF polymorphisms and the symptoms related to ADHD. 
Consistent with our findings, Lee et al.22 reported that par-
ents and teachers rate the inattention and hyperactivity/im-
pulsivity scores of ADHD patients with G alleles higher than 
those of patients with A alleles, but this difference was not 
statistically significant. Conversely, Gadow et al.41 reported 
that the BDNF Met66- group (A alleles) elicited more severe 
parental ratings of ADHD symptoms. Bergman et al.,42 re-
ported that the Met allele (A) of the Val66Met polymorphism 
is associated with the symptoms of ADHD at the ages 8–9 
and that this effect on hyperactivity-impulsivity symptoms in 
ADHD persists at the ages of 13–14 years. These contradic-
tory findings may be due to that fact that the symptomatolo-
gy of ADHD is characterized by developmental heterogene-
ity.43 In contrast, differential genetic components may have a 
role in childhood ADHD with or without the remission of 
the phenotype across the life span.40
In animal studies, BDNF has been related to learning and 
memory functions.24,25 Eagan et al.44 reported that the Val-
66Met polymorphism of the BDNF gene may influence hu-
man hippocampal function and memory. For these reasons, 
we sought to evaluate the neurocognitive functions of chil-
dren with ADHD according to the Val66Met polymorphism, 
but we were unable to find any differences between the poly-
morphism groups. We found only one study that investigated 
the relationship between the Val66Met polymorphism and 
cognitive functions in ADHD. This study was conducted by 
Lee et al.,22 and these authors reported that no association 
was found between BDNF alleles and working memory abili-
ties in their sample of ADHD families. Foltynie et al.45 found 
that Met allele carriers performed better in the Tower of Lon-
don test, which is a measure of planning ability that is used 
for Parkinson’s disease. Conversely, Rybakowski et al.46 re-
ported that the Met allele was associated with worse perfor-
mance compared with the Val/Val genotype in the Wiscon-
sin card sorting test, which is used to measure PFC function 
in bipolar patients. Similarly, studies performed in healthy 
populations have also obtained inconsistent results regarding 
hippocampal function. Two studies indicated decreased hip-
pocampal activation in Met carriers.47,48 Another study re-
ported increased hippocampal activation in Met carriers.49 
One study, which supports our findings, found not differenc-
es between Val66Met groups in hippocampal activity during 
a face recognition task.50 These contradictory findings may 
be due to heterogeneity of the study sample diagnoses. More-
over, the differential effects of the BDNF polymorphism may 
potentially be explained by the complex interactions between 
BDNF and other candidate gene complexes related to cogni-
tive functions.
There are several limitations to the present study. Our study 
included only two ADHD subtypes, i.e., ADHD-I and AD-
HD-C, because ADHD-H is rarely observed clinically. Fu-
ture studies that include the ADHD-H subtype would provide 
more comprehensive information related the psychopatholo-
gy of ADHD. We did not exclude ODD, and the potential 
presence of comorbid ODD in some patients may have cre-
ated the confounding effects. Additionally, we assessed esti-
mated IQ using only the vocabulary and block design subtests 
of the WISC-R. Thus, other potential ADHD neuropsycho-
logical domains were not assessed (e.g., delay aversion and 
RT variability). We did not match the ADHD and TD groups 
in terms of gender although we provided the male predomi-
nance in both groups. Finally, we used saliva samples as the 
DNA source; however, the use of peripheral blood samples 
could have increased the efficiency of the genotyping.
As a conclusion, in the present study, the GG genotype was 
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more frequently observed in the ADHD and ADHD-C sub-
type patients than in the TDs. Consistent with these findings, 
the hyperactivity and inattention symptom counts and total 
scores were higher, and the appropriate behavior scores were 
lower in the subjects with GG genotypes than in those with A-
containing genotypes. Consequently, our findings support the 
hypothesis that the Val66Met polymorphism of BDNF is in-
volved in the pathogenesis of ADHD. Moreover, the polymor-
phism of BDNF may influence the clinic features of ADHD. 
Future studies with larger sample size are needed to clarify the 
relationship between BDNF Val66Met polymorphism and 
pathogenesis of ADHD.
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